Noticias de TEM

Mercado

Noticias del mercado

Últimas noticias sobre TEM — 794 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: TEM ✕ 794 resultados
20/07/2026 TEM_US — Moomoo
Press Release: Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) Into Its AI-Enabled Precision Oncology Platform
20/07/2026 TEM_US — DirectorsTalk Interviews
Tempus AI, Inc. (TEM) Stock Analysis: Navigating a 27.81% Potential Upside in Health Information Services
20/07/2026 TEM_US — Business Wire
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
20/07/2026 TEM_US — lw.com
Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis

La firma representa a la empresa de medicina de precisión basada en IA en la adquisición de la empresa de pruebas de enfermedades moleculares residuales.

20/07/2026 TEM_US — Modern Healthcare
Tempus AI to buy cancer-tech firm Personalis for $1.7B

Se espera que el acuerdo se cierre a finales de 2026 o principios de 2027.

20/07/2026 TEM_US — Stock Titan
Tempus AI (NASDAQ: TEM) plans $1.5B all-stock acquisition of Personalis
20/07/2026 TEM_US — Yahoo Finance
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
20/07/2026 TEM_US — The Business Journals
Tempus AI to acquire Personalis for $1.5B
20/07/2026 TEM_US — Stock Titan
Tempus AI (NASDAQ: TEM) to buy Personalis in $1.5B cancer MRD deal
20/07/2026 TEM_US — Investing.com
Needham reiterates Tempus AI stock rating after Personalis deal
20/07/2026 TEM_US — HIT Consultant
M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring
20/07/2026 TEM_US — Benzinga
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition

Las acciones de Tempus AI caen después de que un acuerdo de Personalis por valor de 1.500 millones de dólares amplíe su alcance en el mercado de MRD de 20.000 millones de dólares.

20/07/2026 TEM_US — finance.biggo.com
Tempus AI Plunges as Investors Question $1.5 Billion Cash Buyout of Personalis

Las acciones de Tempus AI cayeron un 8,8% a 47,81 dólares después de que la compañía anunciara una adquisición en efectivo por 1.500 millones de dólares de la empresa de diagnóstico del cáncer Personalis en...

20/07/2026 TEM_US — Reuters
Tempus to buy cancer test maker Personalis for $1.5 billion
20/07/2026 TEM_US — Bloomberg
Tempus to Buy Cancer-Tech Firm Personalis for $1.7 Billion
20/07/2026 TEM_US — Quiver Quantitative
Tempus AI to Acquire Personalis in $1.5 Billion Deal to Expand Precision Oncology Platform
20/07/2026 TEM_US — Stocktwits
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal
20/07/2026 TEM_US — MLex
US health tech firm Tempus AI plans to acquire cancer diagnostics firm Personalis
20/07/2026 TEM_US — Modern Healthcare
Tempus AI to buy cancer-tech firm Personalis for $1.7B
20/07/2026 TEM_US — Yahoo Finance
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal

Página 36 de 40